New approaches to treatment for alopecia

The Hair Growth CycleA

At birth, each human being possesses between 2 and 5millions vellus hairs or terminal hair follicles and no additional follicles are naturally formed after birth in humans. Of these 1,000,000 are located on the head, and of this total 55,000 to 60,000 follicles are located on the scalp, producing 100,000 to 150,000 hairs. Each hair follicle usually contains 1 to 4 hairs. The hair growth (or life) cycle is asynchronous and consists of 3 phases:

Growing or Anagen Phase

Approximately 80-85% of hairs, i.e. the vast majority, are in this phase. It lasts from 2 to 6 years. Hair is actively growing and materials are deposited in the hair shaft by cells found in the follicle. The cells are proliferating.

Hairs in the growth phase have intense color, grow daily by about 0.035cm, and maintain this rate of growth throughout the anagen phase.

Catagen or Transition Phase

Immediately after the anagen phase, the hair enters the catagen phase. This lasts about 2 to 3 weeks, during which hair follicles cease to be active and cellular division ceases. The regression of the hair follicle in Catagen is characterized by a cessation of protein and pigment production, involution of the hair follicle and a restructuring of the extracellular matrix. A massive apoptosis occurs. Hair follicles shrink in size, hair growth ceases in preparation for apoptosis (shedding). Roughly 1-2% of hair will be in the catagen phase.

Resting or Telogen Phase

The resting phase succeeds the catagen phase and takes about 100 days (3-4 months). The hair follicle has regressed to about half of its previous size. No DNA, RNA and protein synthesis. The Hair is going to fall but the hair shaft (club hair) can be retained for months in the epithelial sac. About 15% of hairs are in the telogen phase.

Normal hair loss

The daily loss of 50-100 hairs is considered normal and can be attributed to the fact that the hair growth cycle is asynchronous, thus some hairs in the telogen phase are shed every day. Seasonal hair loss is also normal and is usually observed in spring and autumn as a result of the reaction of hair follicles to seasonal environmental influences.


Alopecia is the term describing the complete lack or thinning of hair on the head or body due to shedding, or in rare cases to agenesis. Alopecia is the most common hair growth disorder and there are various types, depending on the form, severity or duration of the phenomenon. Alopecia can be divided into the following categories: diffuse (alopecia totalis - loss of all hair on the scalp), circular (alopecia areata - in round patches) and complete (alopecia universalis), and may be either transient or permanent on the one hand, and either scarring (or cicatricial type) or non-scarring on the other. The two main categories are scarring and non-scarring.

Androgenetic Alopecia

This is the most widespread form of male baldness and is responsible for up to 95% of cases of alopecia. It presents as the thinning of hair at the front, the upper section, and the top of the scalp. In males, it begins at puberty, in the second or in the third decade of life. The back and sides of the scalp retain a greater percentage of existing hair.

Experts say that 50% of (Caucasian) men at the age of 40 years have androgenetic alopecia, while this percentage reaches 80% at age 70.

In women, female pattern hair loss (androgenetic alopecia) occurs at the end of the third decade of life (early onset) or post-menopause (late onset) and less frequently than in men. Between the ages of 20 and 30 the percentage of women with female androgenetic alopecia is estimated at 6%-12%, while after the age of 70 it reaches 40%-55%.


The treatments for androgenetic alopecia can be divided into the following categories:

  • Topical treatment - Minoxidil
  • Systemic treatment - Finasteride, Dutasteride etc.
  • Corrective surgery - hair follicle transplantation
  • Camouflage techniques - Use of sprays to dye the scalp; use of electrostatic adhesive sprays to increase hair thickness; wigs and hairpieces made from synthetic or natural hair.

Latest information

The treatment of heavy hair loss is a need which has not as yet been effectively met; there are few innovative suggestions and existing levels of satisfaction are quite low.

The market availability of CG210 is a worldwide first. It has a unique active mechanism for safe and effective treatment of hair loss in both men and women.

CG210’s unique and innovative active mechanism works on three levels:

  • Molecular: Restores the anti-apoptotic protein Bcl-2 towards normal level (+ 89%).
  • Cellular: Increases Langerhans cells (+ 74%), which regulate immune response and exercise anti-inflammatory functions.
  • Cosmetic: Perifollicular collagen is remodeled and increased (+ 67%) resulting in better hair implantation and reduced pore size, therefore less pro-inflammatory stimuli.

The result is that hair loss returns to normal in less than 44 days. The mechanism of action is equally effective in men and women. Clinical studies have shown that topical application increases hair density in the anagen (growth) phase and reduces the number of hairs lost in the telogen phase (shedding).

The product is a combination of active ingredients with clinically proven efficacy in the increase of hair growth and the prevention of hair loss. Its main ingredients are:

  • Allium Cepa extract
  • Citrus Limonum extract
  • Theobroma Cacao extract
  • Paullinia Cupana extract

The product is available in different packaging for men and women. Each box contains 80ml topical solution in spray form for external use.

The dosage for male or female androgenetic alopecia is 5 to 10 sprays twice (2) daily for 9 months, followed by once (1) per day on the entire scalp (wet or dry). The 80ml bottle can lasts from 4 to 8 weeks. For occasional hair loss and thin or weak hair, the dosage is 5 to 10 sprays twice (2 times) daily all over the scalp (wet or dry). The minimum recommended treatment time is 6 weeks.

The product is safe to use and well tolerated, and has been dermatologically tested. It is hypoallergenic, contains no preservatives, pigments, parabens or glycol. It is not oily and has low alcohol content.

International experience of CG 210

Having undergone clinical study and product characteristic analysis:

CG 210 has been available in the largest European countries under the brand name Oenobiol produced by Sanofi since the end of 2013. In France, during the first month after launch the number of new users increased by an average of 1,000 each week.

In Southeast Asia, (Thailand, Singapore, Taiwan, Malaysia, Vietnam, Indonesia, Hong Kong) it was first marketed in October 2014 under the brand name CG 210 by Abbott Laboratories.

In Australia, Switzerland, Russia, Japan, Canada, China, Brazil, South Africa, Mexico, Argentina, Venezuela, Colombia, India, Korea and the Philippines, the product was released by Galderma Pharmaceuticals under the brand name CG 210.

24, Vouliagmeni Avenue, Elliniko,
Attica 16777, Greece

  • Email:
  • Phone: +30 210 9609960
  • Fax: +30 210 9638438



We use the "Cookies" technology to facilitate the use of this website.